Source:http://linkedlifedata.com/resource/pubmed/id/10811504
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2000-7-27
|
pubmed:abstractText |
There is lack of effective and safe chemotherapy for advanced hepatocellular carcinoma. Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) has long circulation time and enhanced drug accumulation in the tumor tissues. It has significant activity in Kaposi's sarcoma, breast and ovarian cancers and the acute adverse effects of free drug are reduced.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0923-7534
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
349-53
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10811504-Adult,
pubmed-meshheading:10811504-Antineoplastic Agents,
pubmed-meshheading:10811504-Carcinoma, Hepatocellular,
pubmed-meshheading:10811504-Doxorubicin,
pubmed-meshheading:10811504-Drug Carriers,
pubmed-meshheading:10811504-Fatal Outcome,
pubmed-meshheading:10811504-Humans,
pubmed-meshheading:10811504-Liposomes,
pubmed-meshheading:10811504-Liver Neoplasms,
pubmed-meshheading:10811504-Male
|
pubmed:year |
2000
|
pubmed:articleTitle |
Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study.
|
pubmed:affiliation |
Department of Oncology, College of Medicine, National Taiwan University, Taipei. rlhong@ha.mc.ntu.edu.tw
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|